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Mycobacterium tuberculosis remains a major cause of morbidity
and mortality worldwide. Studies have reported human pathogens
to have geographically structured population genetics, some of
which have been linked to ancient human migrations. However, no
study has addressed the potential evolutionary consequences of
such longstanding human–pathogen associations. Here, we dem-
onstrate that the global population structure of M. tuberculosis is
defined by six phylogeographical lineages, each associated with
specific, sympatric human populations. In an urban cosmopolitan
environment, mycobacterial lineages were much more likely to
spread in sympatric than in allopatric patient populations. Tuber-
culosis cases that did occur in allopatric hosts disproportionately
involved high-risk individuals with impaired host resistance. These
observations suggest that mycobacterial lineages are adapted to
particular human populations. If confirmed, our findings have
important implications for tuberculosis control and vaccine devel-
opment.
coevolution  deletions  lineage  polymorphism  population
Several studies have reported geographically structured pop-ulations in human pathogens (1–4). Recently, the genetic
population structure of Helicobacter pylori and Mycobacterium
leprae have been linked to ancient human migrations (1, 4, 5).
Such long-standing host–pathogen associations could lead to
adaptive genetic changes between interacting host and pathogen
populations. Studies in invertebrate model systems have shown
that pathogens can adapt to specific host species (6). However,
no example of host-specific pathogen adaptation has yet been
documented in pathogens affecting different human popula-
tions. The observation of geographically structured populations
of human pathogens implies that particular strains and their
corresponding patient populations can be classified as sympatric
or allopatric (6). Compatibility, defined as the ability of a given
pathogen to infect a particular host, often differs in sympatric
versus allopatric host–pathogen combinations, with sympatric
combinations usually displaying a greater compatibility (6).
Mycobacterium tuberculosis occurs world-wide and is still
killing 2–3 million people each year (7). New tools for tubercu-
losis control are urgently needed, including a more effective
vaccine (8). A series of genotyping tools forM. tuberculosis have
been developed (9). Most of these make use of mobile genetic
elements or repetitive DNA. Even though these tools have been
invaluable for detecting ongoing tuberculosis transmission, the
markers upon which they are based change relatively rapidly,
making it difficult to define deep phylogenetic relationships (4).
In contrast, large sequence polymorphisms (LSPs) represent
unique event polymorphisms that can be used to construct robust
phylogenies for M. tuberculosis (10). An additional advantage is
that, once LSPs have been identified (e.g., by comparative
whole-genome hybridization), simple PCR can be used to screen
large numbers of strains in a high-throughput fashion.
In this study, we used comparative genomic and molecular
epidemiological tools to define the global population structure
of M. tuberculosis and to investigate its influence on the trans-
mission dynamics of M. tuberculosis in San Francisco during an
11-year period.
Results and Discussion
To define the global population structure of M. tuberculosis, we
performed genomic deletion analysis on a global sample of 875
strains originating from 80 countries (Table 1 and Table 3, which
is published as supporting information on the PNAS web site).
This sample included strains isolated from foreign-born tuber-
culosis patients in San Francisco who contracted the infection in
their country of origin and was complemented with geograph-
ically representative strains from other reference collections. We
analyzed a subset of 111 strains by comparative whole-genome
hybridization (11). The results of 74 of these experiments were
published earlier (11–13), and 37 are reported herein. Overall,
we identified 19 phylogenetically informative and lineage-
specific LSPs (Fig. 1a and Table 4, which is published as
supporting information on the PNAS web site). These LSPs were
confirmed by sequencing, validated by PCR and sequencing in 72
additional strains, and used to screen the remaining 692 strains
by PCR or multiplex real-time PCR (Table 4 and Table 5, which
is published as supporting information on the PNAS web site).
We used as additional phylogenetic markers the previously
reported regions of difference (RD) TbD1 and RD9 (ref. 14),
the 7-bp deletion in the pks151 locus (15), and the katG463 ctg
to cgg substitution (16).
The analysis of our global sample of 875 strains revealed six
main lineages and 15 sublineages of M. tuberculosis (Fig. 1a,
Tables 1 and 3, and Table 6, which is published as supporting
information on the PNAS web site). Some of these lineages
correspond to strain groupings that have previously been re-
ported. For example, the Indo-Oceanic lineage includes a group
of strains that have been referred to as ‘‘ancestral’’ due to the fact
that they conserve the TbD1 genomic region, which is deleted in
‘‘modern’’ strains ofM. tuberculosis (14). The East-Asian lineage
includes, but is not limited to, the Beijing family of strains (13).
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The West-African lineages 1 and 2 correspond to strains that
have traditionally been named Mycobacterium africanum (12),
and the Euro-American lineage regroups strains that have
generally been described as principal genetic groups 2 and 3
(15–17).
Besides confirming some of the mycobacterial groupings that
have been described previously, our analysis of an extended
global strain collection revealed that the population genetics of
M. tuberculosis is highly geographically structured. Each of the
six main lineages was associated with particular geographical
areas, and the lineage names reflect these geographical associ-
ations (Fig. 1b and Table 1). For example, the East-Asian lineage
is dominant in many countries of the Far East, and the Indo-
Oceanic lineage occurs all around the Indian Ocean. The
Euro-American lineage is clearly the most frequent lineage in
Europe and the Americas, but specific sublineages within the
Euro-American lineage predominate also in different regions of
Africa and the Middle East (Fig. 1). Although we did observe
such geographical substructuring within the Euro-American
lineage, no other sublineage was associated with any specific
geographical area (results not shown).
Although most other areas were associated with only one or
two lineages, all six main lineages were represented in Africa
(Fig. 1b). These lineages included the twoWest-African lineages
that did not occur elsewhere, as well as the Indo-Oceanic lineage,
the most ancestral of the six lineages, which was associated with
East Africa. A recent study suggests that ancestral mycobacteria
may have already affected early hominids in East Africa around
3 million years ago (18). Taken together, these findings are
consistent with a scenario for the origin and evolution of human
tuberculosis in which M. tuberculosis expanded and diversified
during its spread out of East Africa. This speculative scenario
Table 1. Assignment of 875 strains of M. tuberculosis from 80 countries to six main phylogenetic lineages in eleven
geographic regions
Geographic region
(no. of countries) Total strains
Indo-Oceanic
lineage
East-Asian
lineage
East-African-Indian
lineage
Euro-American
lineage
West-African
lineage 1
West-African
lineage 2
Americas (18) 207 6 7 194
Europe (14) 35 1 4 30
North AfricaMiddle East (6) 10 10
West Africa (8) 28 12 9 7
Central Africa (5) 15 1 14
South Africa (1) 5 2 3
East Africa (6) 20 3 8 9
Indian Subcontinent (4) 17 3 1 10 3
Southeast Asia (9) 272 169 73 1 29
East Asia (7) 262 17 190 55
Pacific Islands (2) 4 4
Total (80) 875 199 277 20 363 9 7
Fig. 1. The global population structure and geographical distribution ofM. tuberculosis. (a) LSPs define a global phylogeny forM. tuberculosis. The names of
the lineage-defining LSPs or regions of difference are shown in rectangles. The geographic regions associated with specific lineages are indicated. (b) The six
main lineages ofM. tuberculosis are geographically structured. Each dot corresponds to 1 of 80 countries represented in the global strain collection. The colors
of the dots relate to the six main lineages defined in Fig. 1a and indicate the dominant lineage(s) in the respective countries.
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suggests that M. tuberculosis might be significantly older than
previously estimated (16). As a consequence, different M. tu-
berculosis lineages may have adapted to different human host
populations.
Taking advantage of the cosmopolitan setting of San Fran-
cisco, with its diverse tuberculosis patient and bacterial popu-
lations, we investigated the effects of host–pathogen mixing on
the occurrence of secondary cases of tuberculosis. We used
multiplex real-time PCR to screen for the main lineages of M.
tuberculosis in a stratified random sample of 1,321 isolates,
corresponding to 71% of all tuberculosis cases reported in San
Francisco between 1991 and 2001 who were born in the United
States (U.S.), China, The Philippines, Vietnam, or Central
America. These patients represent the five largest tuberculosis
patient populations in San Francisco. This sample included all of
the restriction fragment length polymorphism (RFLP) clustered
cases belonging to any of these five populations as well as a
random sample of unique cases. The clustered cases were
considered part of chains of relatively recent tuberculosis trans-
mission in San Francisco, and the unique cases were considered
to have developed tuberculosis as a consequence of reactivation
of latent infection (19).
Our results showed that 99.6% of all isolates in San Francisco
belonged to three of the six main lineages. Twenty-six percent of
the 1,321 isolates belonged to the Indo-Oceanic lineage, 26% to
the East-Asian lineage, and 48% to the Euro-American lineage.
When we stratified the bacterial lineage data by the five patient
populations, a strong association was evident (Fig. 2a; Pearson
28  1295, P  0.0001). In four of the five patient populations,
one specific lineage accounted for at least 72% of all tuberculosis
cases.
We explored whether the association between lineage of M.
tuberculosis and human population reflects host-specific differ-
ential transmission of mycobacterial lineages using RFLP clus-
tering as a proxy for transmission (20). We hypothesized that
lineages that are rare in a specific human population are not
adapted to transmit and cause secondary cases in this specific
human population. We first calculated the secondary case-rate
ratios of the three M. tuberculosis lineages irrespective of the
patient’s place of birth. All three lineages had statistically
different secondary case rate ratios (Table 7, which is published
as supporting information on the PNAS web site). In San
Francisco, patients infected with the Euro-American lineage
were three times more likely to generate a secondary case during
the 11-year study period than patients infected with any other
strain. The Indo-Oceanic lineage had a significantly lower
secondary case-rate ratio and the East-Asian lineage the lowest.
When we calculated the lineage-specific secondary case-rate
ratios stratified by human population, we found that, in every
instance, the secondary case-rate ratios of sympatric lineages
were significantly greater in comparison with that of allopatric
lineages in the same population (Fig. 2b and Table 7). Taken
together, these observations suggest that particular lineages of
M. tuberculosis might be adapted to specific human populations
and maladapted to others.
Given that some tuberculosis cases were caused by allopatric
lineages, we investigated the characteristics of patients with
disease caused by allopatric lineages. We chose to look at the
U.S.-born population because it represents the largest patient
population in San Francisco (Fig. 2a) and because sociological
determinants of transmission are well documented. The char-
acteristics of the U.S.-born patients, stratified by the three
lineages of M. tuberculosis, are presented in Table 8, which is
published as supporting information on the PNAS web site.
Significant variables were selected for multivariate logistic re-
gression modeling. The multivariate analysis revealed that U.S.-
born patients of self-defined Chinese and Filipino ethnicity tend
to harbor the same strains as patients born in China and the
Philippines, respectively (Table 2). Because self-defined ethnic-
ity is a good predictor of human genetic ancestry (21), these
findings provide significant additional support for the impor-
tance of this host–pathogen association.
Another study has reported similar associations between M.
tuberculosis strain families and human populations (17). Such
host–pathogen associations, although indicative, do not by them-
selves provide proof that specific host–pathogen adaptations
occur. They can also be explained by sociological and epidemi-
ological factors (6). For example, social mixing is nonrandom
among ethnic groups in San Francisco, which certainly impacts
Fig. 2. Lineage-specific prevalence and transmission of M. tuberculosis in
San Francisco (1991 to 2001). (a) Prevalent strains in San Francisco are strongly
associated with sympatric patient populations. The sums of both unique and
clustered cases are shown. (b) The propensity of specific mycobacterial lin-
eages to transmit is significantly higher in sympatric comparedwith allopatric
patientpopulations.*, comparisonwith theother two lineages combined,P
0.0001; yellow, Indo-Oceanic lineage; blue, East-Asian lineage; red, Euro-
American lineage.
Table 2. Risk factors independently associated with one of
three M. tuberculosis lineages in 490 U.S.-born patients
from San Francisco
M. tuberculosis
lineage Risk factor
Adjusted
odds ratio (95% CI) P value
East-Asian Chinese ethnicity 19.8 (4.6–84.2) 0.001
Homelessness 3.0 (1.4–6.2) 0.004
Indo-Oceanic Filipino ethnicity 43.2 (5.6–335) 0.001
Age 45 years 3.9 (1.5–10.1) 0.004
HIV positive 3.4 (1.3–8.7) 0.01
Euro-American Chinese ethnicity 0.18 (0.06–0.6) 0.004
CI, confidence interval.
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transmission of M. tuberculosis between U.S.- and foreign-born
individuals in the short term (22, 23). However, some foreign
strains, for example those associated with Chinese immigrants,
must have been introduced into San Francisco repeatedly since
the beginning of the Gold Rush in the 1800s (http:
en.wikipedia.orgwikiChinatown%2CSanFrancisco). We
propose that over such large time frames, there has been ample
opportunity for the spread of foreign strains into the U.S.-born
population.
We cannot exclude the possibility that social factors contribute
or even drive our observation of lineage-specific association with
particular human populations. However, further results from our
multivariate analysis support biological causality for the ob-
served host–pathogen association. U.S.-born tuberculosis pa-
tients of non-Chinese and non-Filipino ethnicity infected with
allopatric strains (i.e., belonging to the Indo-Oceanic or East-
Asian lineages) were more likely to be HIV-positive or homeless
(Table 2). This finding suggests that, although these lineages are
less adapted to transmit and cause disease in fully competent
members of allopatric human populations, they can do so in the
context of impaired host resistance. Such differences in host–
pathogen compatibility or local adaptation have been associated
with host-specific pathogen adaptation and have been demon-
strated in several invertebrate host–pathogen model systems (6).
Conclusions
Overall, our findings demonstrate a global genetic population
structure for M. tuberculosis and support the notion that this
pathogen has adapted to specific human populations. These
results have implications for tuberculosis control efforts, espe-
cially for the development of new vaccines. The importance of
strain genetic variation for vaccine escape has been documented
in several bacterial species (24–26). In bacillus Calmette-Gue´rin
(BCG), the currently available tuberculosis vaccine, significant
geographical variation in protective efficacy has been observed
(8). Environmental factors and differences in vaccine strain have
been invoked (8, 27–29), but our findings suggest that regional
differences in host–pathogen interactions could be partially
responsible. Although recent progress has been made in the
development of new tuberculosis vaccines (30), the global pop-
ulation structure of M. tuberculosis and host-specific pathogen
adaptation may need to be considered when engineering and
evaluating new vaccine candidates.
Materials and Methods
Molecular Epidemiology in San Francisco. In an ongoing population-
based molecular epidemiological study in San Francisco, CA
(19), 2,807 tuberculosis patients were enrolled between January
1991 and December 2001. Of these patients, 2,382 (84.9%) had
M. tuberculosis isolated in culture. Demographic and epidemi-
ological data, including place of birth and self-defined ethnicity,
were recorded for each patient, and IS6110 RFLP genotyping
was performed on 2,141 (89.9%) of the bacterial isolates fol-
lowing standardized methods (19). Isolates with fewer than six
IS6110 copies were further genotyped by polymorphic GC-rich
sequence (PGRS) RFLP (9). Isolates with matching (clustered)
RFLP patterns were considered part of a chain of relatively
recent tuberculosis transmission. The protocols and the proce-
dures for the protection of human subjects were approved
by Stanford University and the University of California, San
Francisco.
Global Sample of M. tuberculosis.Fifty of the strains included in the
global sample had unique RFLP patterns and were isolated from
U.S.- and foreign-born patients from San Francisco. We previ-
ously reported that these patients represented cases of reacti-
vation of infections acquired in their respective country of origin
and that the genomic deletion profiles of these strains were
associated with the respective patient’s place of birth (10).
Therefore, the unique foreign-born cases from San Francisco
could be used to sample the diversity of M. tuberculosis. We
validated this approach in 108 reference strains obtained from
several additional strain collections representative of specific
geographic areas (Table 3). These reference strains were se-
lected because they represented the most common genotypes in
the corresponding geographic areas based on our previous
molecular epidemiological studies (9, 31) (B.C.d.J., S. Naray-
anan, M.N., S. Niemann, and M.H., unpublished results). We
then screened an additional 709 unique strains isolated from
U.S.- and foreign-born patients from San Francisco. Eight
strains from different patient clusters comprising only U.S.-born
individuals were also included.
Identification of Large Sequence Polymorphisms. Comparative
whole-genome hybridization was performed by using an Af-
fymetrix (Santa Clara, CA) DNA chip, following procedures
described previously (11). Genomic regions putatively deleted in
the test strains compared with the sequenced reference strain
H37Rv were identified by using DELSCAN software (AbaSci, San
Pablo, CA). Putative deletions were confirmed by PCR and
sequencing (11).
Lineage Determination by PCR andMutliplex Real-Time PCR.Weused
the phylogenetically informative LSPs to screen by PCR andor
TaqMan multiplex real-time PCR (Applied Biosystems) in the
unique strains and one isolate representative of each of the 184
(97.7% of all) patient clusters that occurred in San Francisco
between 1991 and 2001. The screening results from the clustered
isolates were extrapolated to the remaining isolates of the
respective clusters. The primer and probe sequences used in this
study are shown in Tables 4 and 5. The Euro-American lineage
was defined based on a characteristic 7-bp deletion in pks151
(ref. 15) or the ctg to cgg substitution at codon 463 of katG (ref.
16), which are known to be equivalent markers (15, 17).
Lineage-Specific Transmission in San Francisco. Of 2,141 patients
with available RFLP data, 1,849 (86.4%) were born in the U.S.,
China, the Philippines, Central America including Mexico, and
Vietnam. This set of 1,849 patients represented our sampling
frame. We classified these patients as follows: all clustered
patients, all cases with drug resistance, all patients born in
Vietnam or in Central America for which DNA was available,
and a random selection of strains with unique RFLP patterns
recovered from patients born in the U.S., China, or the Philip-
pines (the three largest patient populations in San Francisco).
Overall, 71.4% of eligible patients (1,3211,849 patients) and
their isolates were included in this part of the study, comprising
66.6% (493740) of patients born in the U.S., 67.3% (301447)
of patients born in China, 69.5% (251361) of patients born in
the Philippines, 89.7% (140156) of patients born in Central
America, and 93.8% (136145) of patients born in Vietnam.
Statistical Analysis. The number of secondary cases in each
lineage was determined by subtracting the number of RFLP
clusters from the total number of clustered cases (20). Because
prevalent bacteria have a greater opportunity to transmit, we
translated the number of secondary cases in each lineage into
lineage-specific secondary case rates by dividing the number of
secondary cases in a lineage by the sum of all index cases (the
number of clusters plus all of the unique cases) belonging to the
same lineage. To compare transmission rates between lineages,
we then transformed the lineage-specific secondary case rates
into secondary case-rate ratios by dividing the secondary case
rate of the lineage of interest by the secondary case rate of the
other two lineages combined. To calculate the host population-
specific secondary case rate, wemade the simplifying assumption
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that any index case in San Francisco, regardless of which host
population he or she belonged to, could have infected the
secondary case in question. Thus, we used as the denominator
the sum of the number of clusters plus unique cases for the whole
of San Francisco. A total of 188 patient clusters with 604
secondary cases occurred in San Francisco between 1991 and
2001. For the analysis, there were 184 clusters (97.9%) with their
corresponding 596 (98.7% of all) secondary cases with at least
one isolate with DNA available for screening. Overall, 1,349
tuberculosis cases with a unique RFLP pattern occurred during
the same time period, 754 (55.9%) of which had lineage infor-
mation available (including 213 cases who were not part of the
five main patient populations). To account for the number of
unique cases that were not screened for lineage-defining mark-
ers, we weighted the denominator of the secondary case rate by
multiplying the number of unique cases in each lineage by 1.79
(1,349 total unique cases754 screened unique cases).
To identify the risk determinants of transmission of allopatric
strains in the U.S.-born population, we sought associations
between the three lineages and patient characteristics using
univariate analyses with a 3  2 2 test of proportions with two
degrees of freedom. Variables with a P value 0.20 in the 3 
2 comparison were further tested by individual 2  2 compar-
isons by using the regular 2 test of proportions or Fisher’s
two-tailed exact test. All variables with a P value0.20 in the 2
2 univariate analysis and biological plausibility were considered
for the multivariate logistic regression model. We performed
forward stepwise model construction and compared the log
likelihood ratios of successive models until the final, most
parsimonious model was identified. We used the Hosmer-
Lemeshow goodness-of-fit test to validate the final models (32).
Statistical analyses were performed with STATA 7E (Stata Cor-
poration, College Station, TX).
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